Business
Avicanna Announces Changes to its Board of Directors
TORONTO, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products, announces Mr. Paul Fornazzari’s resignation from the Company’s board of directors, and is pleased to announce the appointment of Mr. Michael Kott to its board of directors. Michael Kott will join the board January 1, 2026, is an experienced
About this update from Avicanna Inc
[{"type":"image","alt":"Avicanna Inc.","displaySize":"","headline":null,"caption":"Avicanna Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":300,"url":"https://media.zenfs.com/en/globenewswire.com/1c68da9c20a644cdc756241b8ad53506"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/vToBXKkzxq5ehGv_5f_3zA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/1c68da9c20a644cdc756241b8ad53506","width":300,"height":300}},"lazy":false},{"type":"text","content":"TORONTO, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products, announces Mr. Paul Fornazzari’s resignation from the Company’s board of directors, and is pleased to announce the appointment of Mr. Michael Kott to its board of directors.","length":432,"tagName":"p"},{"type":"text","content":"Michael Kott will join the board January 1, 2026, is an experienced Chief Executive Officer, entrepreneur, and investor with more than 35 years of expertise in international capital markets, corporate finance, and fundraising. Mr. Kott is the Founder and Chief Executive Officer of CM-Equity AG, which he built into a regulated investment bank operating across Europe under MiFID II before transitioning it in 2025 into a global single-family office focused on long-term value creation. Mr. Kott has an extensive track record serving on public and private company boards, with deep expertise in governance, compliance, capital markets transactions, IPOs, and cross-border investments. He is an active independent investor across public equities, venture capital, and alternative assets, with experience spanning biopharma and longevity, technology, cleantech, and sustainability.","length":879,"tagName":"p"},{"type":"text","content":"“I am excited for the opportunity to join the board of Avicanna Inc. and support the exciting next stages of the growth and evolution. I believe that Avicanna is in the centre of the evidenced based natural pharmaceuticals megatrend and has the potential to make a significant impact. Their strategy and vision were further validated by the recent communications from the White House on steps towards near term reclassification o...